Preliminary Results from a Phase 1-2 Gene Therapy Study of ATA-100, AAV9 Vector Encoding FKRP, in Patients with Limb Girdle Muscular Dystrophy R9

WMS 2024 Oral Presentation

Sophie Olivier, MD, Chief Medical Officer, Atamyo Therapeutics